Clinical Trial Detail

NCT ID NCT01562873
Title Ruxolitinib in Patients With Breast Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

breast cancer

triple-receptor negative breast cancer

Therapies

Ruxolitinib

Age Groups: adult senior

No variant requirements are available.